APO-1 is a 48-Kd transmembrane glycoprotein identical to the Fas antigen and belongs to the nerve growth factor (NGF)/tumor necrosis factor (TNF) receptor family of surface molecules. Cross-linking of APO-I induces apoptotic cell death in sensitive cells. We show here that APO-1 is an activation molecule on B cells. It was induced/enhanced on dense and buoyant tonsillar B cells, respectively, through surface lg cross-linking in combination with interleukin-2 or by interferon-y together with tumor necrosis factor-a. These conditions also increased the amount of intercellular adhesion molecule-I (CD54) on these cells. Epstein-Barr virus transformants of peripheral B cells coexpressed APO-1 and CD54 at very high levels. Immunohistologically, Apo-1 was detectable at low levels in a subpopulation of follicle center B blasts and, at higher levels, in sinusoidal B cells. APO-1 was undetectable in follicular mantle B cells and plasma cells. In isolated tonsillar B cells, APO-1 was ex-E DESCRIBED a 48-Kd cell membrane protein, APO-1, recognized by the monoclonal antibody (MoAb) anti-APO-1. APO-1 is expressed on human leukemia virus type-1 -transformed T-cell lines, cultured cells from patients with adult T-cell leukemia, activated normal T and B cells, Epstein-Barr virus (EBV) transformed lymphoblastoid B-cell lines (LCL), and on some B-lymphoma Outside the immune system, APO-1 is immunohistochemically detectable in several epithelial and in a few activated mesenchymal cell types.3a Cross-linking of APO-1 with anti-APO-1 induces apoptosis in APO-I+, apoptosis-sensitive cells in vitro: In vivo, anti-APO-1 induced tumor regression of a human Bcell lymphoma (BJAB) in nu/nu mice by apopt~sis.~ The MoAb anti-Fas, previously described by Yonehara et al,' has an in vitro activity similar to that of anti-APO-1. Cloning of the APO-I and the Fas antigen showed that both MoAbs recognize the same The APO-1 antigen is a cysteine-rich transmembrane glycoprotein of 335 amino acids and belongs to the nerve growth factor (NGF)/tumor necrosis factor (TNF) receptor superfamily. The human APO-1 gene is located on chromosome lOq23.' The putative physiologic ligand of APO-l/Fas is still unknown. Recently, the lymphoproliferative disorder in Ipr//pr mice could be traced to a mutation in the gene encoding the murine A P O -~/ F~S .~. '~ One symptom of the murine /pr//pr syndrome is the generation of autoantibodies. This was shown to be due to a genuine B-cell and might be explained by a failure of autoimmune B cells to undergo apoptosis."
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The intercellular adhesion molecule-1 (ICAM-1 ; CD54), a member of the Ig superfamily, is a 90-Kd integral membrane glycoprotein with five Ig-like domains.13 Low CD54 expression on B cells is enhanced by pokeweed mitogen, anti-IgM antibody,14 and formalinized Staphylococcus aureus Cowan I (SAC) in combination with interleukin-2 (IL-2).I5 CD54 is therefore classified as an activation antigen. ICAM-1 is a ligand of the lymphocyte function-associated antigen-1 (LFA-1; CDl 1a/CD18)16 and ofCDl lb/CD18,'7,18 thus mediating pressed in CDIO+ follicle center cells. In acute B lymphoblastic leukemia, chronic B lymphocytic leukemia, and Burkitt's lymphomas, APO-1 and CD54 molecules were immunohistochemically undetectable. Coordinate expression of these antigens was found in mediastinal B-cell lymphomas. The mode of APO-1 and CD54 expression was correlated in follicle center cell lymphomas (P < .0019), but less stringently in hairy cell leukemia. No association was found in plasmacytomas. This was in line with the differential expression of these molecules found in reactive plasma cells. Expression of APO-1 in B cells of different stages of differentiation and, correspondingly, in certain Bcell neoplasias might suggest a role of this molecule in the induction of B-cell apoptosis. This function might be influenced by CD54 and CD54-mediated signals. adhesion, B-cell homotypic adhesion in~1uded.l~ Another natural ligand of CD54 is sialophorin (leukosialin, CD43)." It has been shown that susceptibility for T-cell-mediated lysis of T-leukemia cells is critically dependent on the presence of CD54 on the target cells. 21 We show here that APO-1 and CD54 are coregulated in tonsillar B cells and are coordinately expressed during important steps of B-cell differentiation such as the follicle center reaction, whereas both molecules are differentially expressed at the plasma cell level. As determined by immunohistochemistry, most B-cell leukemias and lymphomas, according to their maturational phenotype, coordinately express or lack APO-1 and CD54, respectively. In plasmacytomas, accordingly, both molecules were differentially expressed.
MATERIALS AND METHODS
To determine the physiologic expression of APO-I and ICAM-1 (CD54) in B-cell subpopulations of the normal lymphoid system, cervical lymph nodes (including several specimens affected by toxoplasmic lymphadenitis) and infantile thymus obtained during cardiotomy were chosen as From the quick-frozen tissues. serial frozen sections of about I cmz in area and 4 to 6 pm in thickness were airdried ovemight, fixed in acetone for IO minutes at room temperature, and immunostained immediately or stored at -2OOC for I to 3 weeks. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From APO-1 ON NORMAL AND NEOPLASTIC B CELLS 2069 centrifugation, followed by depletion of monocytes/macrophages by treatment with 2.5 mmol/L L-leucine methyl ester for 40 minutes at room temperature. Tonsillar B lymphocytes were prepared by two subsequent cycles of rosetting with 2-aminoethylisothiouronium bromide (AET)-treated sheep red blood cells and Ficoll-Hypaque gradient separation. This procedure led to residual (CD3+) T-cell contaminations that were regularly below 3%. The enriched B lymphocytes were resuspended in 80% Percoll (Biochrom, Berlin, Germany) at approximately 5 X IO' cells/mL and layered under Percoll step gradients in 15-mL conical tubes with 3 mL of 70% (1.086 g/ mL), 55% (1.069 g/mL), 40% (1.052 g/mL), and 30% (1.040 g/mL) Percoll. After centrifugation at 1,600g for 20 minutes, cells from the 40/55% and 55/70% Percoll interfaces were isolated and referred to as "D40/55" (buoyant B cells) and "D55/70" (dense B cells). "Buoyant" and "dense" B cells were stimulated with 0.001% formalinized SAC (Calbiochem, San Diego, CA) and 20 U/mL rIL-2 (Boehringer Mannheim, Mannheim, Germany) for 72 hours and, alternatively, with 100 U/mL recombinant interferon-y (rIFN-y; Boehringer Mannheim) in combination with 100 ng/mL recombinant tumor necrosis factor-a (rTNF-a; Boehringer) for 24 hours. Immunofluorescent staining was performed in polystyrene round-bottom tubes (Falcon, San Jose, CA). Dilutions and washings were performed throughout in RPMI 1640 medium (GIBCO) containing 2% heat-inactivated FCS, 0.1 % sodium azide, and 10 mmol/L HEPES. Approximately IO6 cells per sample, suspended in 50 pL of medium, were incubated at 4°C with an equal volume of the appropriate dilution of each MoAb. After 45 minutes, cells were washed twice in 500 pL of cold medium, and 2 pg ofF(ab')2 goat antimouse IgG and IgM fluorescein isothiocyanate (FITC) conjugate (Jackson Immunoresearch, West Grove, PA) was added for 45 minutes at 4°C. Cells were washed again twice and resuspended in 300 pL of medium containing 1 pg/mL propidiumiodide (Sigma, St Louis, MO). From each sample the green fluorescence of lo4 cells was analyzed. For double-labeling experiments, bound biotinylated F(ab)* fragments of anti-APO-1 were detected via a streptavidinphycoerythrin conjugate (Dako, Copenhagen, Denmark) and the second antigen via unconjugated primary antibody detected by affinity-purified Fc-specific dichlorotriacinylaminofluorescein-conjugated F(ab'I2 fragment goat-antimouse IgG (Jackson). Dead cells were removed from analysis by selectively gating on propidiumiodine fluorescence, using forward and side scatter parameters. Flow cytometry was performed on a FACScan cytometer with the LYSYS I1 software (Becton Dickinson).
The method is described in detail elsewhere.28 MoAbs in culture supernatants were used undiluted, ascites preparations were used as 1:200 dilutions, and purified reagents were used in a protein concentration of IO pg/mL. A polyclonal biotinylated sheep antibody to mouse Ig (reactive with all mouse isotypes) and a streptavidin-biotinylated peroxidase complex, all obtained from Amersham (High Wycombe, UK), served as a detection system for the primary antibodies. 3-Amino-9-ethylcarbazole (Sigma) was used as substrate for the enzyme; the peroxidase reaction resulted Flow cytometry.
Immunohistologic stainingprocedures.
in an intense red precipitate. The sections were faintly counterstained with Hams' hematoxylin.
Controls and evaluation of antigen density in tissue sections. Negative controls were performed without the primary antibody in each individual case and, in a limited number of cases, by using several irrelevant MoAbs of different mouse Ig isotypes and directed against nonhuman antigens. No staining was observed, except for the reaction of granulocytes whose endogenous peroxidase was not destroyed. Strongly stained dendritic stromal cells, histiocytic cells, and/or T-lymphocytes, always present in various amounts, served as intrinsic positive controls. At the same time, they were taken as internal parameters for the maximum reactivity, which was regarded as "high antigenic density" and symbolized by "+++." A definitely weaker staining intensity of the target cell population was characterized as "low antigenic density" and symbolized by "+." The absence of specific staining was symbolized by "-." Whenever the staining intensity within a B-cell compartment was heterogenous, a simple semiquantitative statement was made. For comparative visualization of the entire B-cell population, a CD19 immunostaining in combination with a CD38 staining was used.
Fisher's exact test was applied for analysis of contingency tables.
Statistical analysis of immunohistochemical results.

RESULTS
APO-1 and CD54 expression in normal B cells. As shown
by immunohistochemistry, APO-1 expression at low levels was regularly detectable in a major subpopulation of follicle center B blasts (Table I and Fig l a and b) . These cells were located in the basal, so-called dark zone of the follicle centers (FC) and could clearly be distinguished from follicle dendritic cells, which in this site were devoid of APO-1. In the light zone of the follicle center, the assessment of APO-1 expression in B blasts was hampered by the strongly stained dendritic network. Mantle zone B lymphocytes (MZ) and mature plasma cells were unstained in all sites examined. Epitheliumassociated (EF) B cells that morphologically resemble small, cleaved follicle center B cells in the mucosa-associated lymphoid tissues (Fig la) and that have small dendritic cytoplasmic extensions within the thymic medulla lacked detectable APO-l (Fig 2a and b) . Sinusoidal (synonymous monocytoid) B cells giving rise to the so-called sinusoidal Bcell reaction (as seen in toxoplasmic lymphadenitis and lymphadenopathy d u e to early h u m a n immunodeficiency virus [HIV] infection) expressed APO-1 at high levels (Fig  2c) . APO-1 expression i n follicle B cells essentially corresponded t o that of ICAM-I (CD54). Although serial section analysis showed the existence of APO-1' a n d CD54-center B blasts, the majority of these cells carried both antigens at the cell surface (Fig 1 b and c) . However, outside the follicle, considerable differences emerged: sinusoidal B cells were APO-1-positive (Fig 2c) at high levels, but lacked C D 5 4 (Fig  2d) . Vice versa, C D 5 4 was expressed at high levels in thymic medullary B cells i n the absence of detectable APO-1. Furthermore, plasma cells in/on which APO-l was undetectable expressed CD54 in the (extrafollicular) subpopulation. These results could be supported in part and extended by cytofluorometric analysis of tonsillar B-cell isolates (Table 2) .
Small "dense" B cells (physical density 55/70%) were practically devoid of APO-1 and expressed CD54 at low levels. Fig 3a) . In a double-labeling flow cytometric experiment (Fig  3b) , it could be further substantiated that the buoyant fraction contained APO-I' follicle center B cells. The dense fraction (physical density 55/70%) was mainly composed of APO-1 IgD' cells (7 I .7%), whereas the majority of the buoyant fraction (physical density 35/50%) consisted of APO-I +IgD-cells (63.5%). Immunohistochemically, surface expression of IgD in tonsillar B cells is restricted to the mantle zone. In peripheral B cells, CD IO expression is restricted to the follicle center stage of maturation.*' As shown in Fig 3b, In vitro, expression of APO-I and CD54 was coordinately enhanced by activation signals. Short-term cultures showed that stimulation through a combination of IFN-y and TNF-a led to a minor increase ofsurface APO-I and CD54 that was more distinct in the dense B e l l fraction (Fig4a). Furthermore, SAC/ IL-2 had an inducingjenhancing e f f i on tonsillar B cells that was more pronounced in the buoyant fraction (Fig 4b) .
55%) coexpressed both molecules at higher levels (
APO-I and CD.54 erpression in EB V-rransformed B I-vmph0cyre.y. LCL resulting from EBV transformation of both peripheral and tonsillar B cells showed levels of APO-I and CD54 expression that regularly exceeded that of in vitroactivated tonsillar B cells by about five times (Fig 5) . Tables 3 and 4 . The acute B-lymphoblastic leukemias (CDIO', CD19+; data not shown) and the B-chronic lymphocytic leukemias examined did not show APO-1 or CD54 expression. Except for a single case that expressed minimal levels of APO-1, all Burkitt's lymphomas were also negative in both respects. On the other hand, APO-1 and CD54 were expressed at high levels in 23 of 25 cases of thymic (primary mediastinal) B-cell lymphoma, whereas the two remaining tumors of this lymphoma variant lacked both antigens (Fig  6a) . Thus, there was a stringent correlation of APO-1 and CD54 expression in these four types of malignant B-cell proliferations. The correlation was less strict, albeit statistically highly significant (P < .OO 19), in follicle center cell lymphomas. Irrespective of the subtype according to the Lukes/Collins or the Kiel classification, follicle center cell lymphomas showed a heterogenous APO-1 and CD54 expression. APO-1 density in the majority of follicle center cell lymphomas was abnormally high as compared with that of reactive follicle center cells (Fig 6b) . Only 10 of 42 tumors of this category were APO-1-. Follicle center cell lymphomas expressed CD54 at comparably lower levels or even lacked this molecule. All APO-1 ~ follicle center cell lymphomas except one were also devoid of CD54 (Table 4) . APO-1 expression was generally low in hairy cell leukemias. Nevertheless, cytometrical comparison of chronic B-lymphocytic leukemia cells and hairy cell leukemia cells showed a clear-cut difference in surface antigen density (Fig 5) . The relation of APO-1 and CD54 expression in hairy cell leukemias remained unclear in our series. Most cases of hairy cell leukemia showed low levels of CD54 or were negative. Nevertheless, there was no clearcut evidence for coordinate expression of both molecules in this type of tumor. Reflecting the reactive counterpart, plasmacytomas were essentially APO-1-but markedly heterogenous in CD54 expression. Thus, the linkage of APO-I and CD54 expression apparently did not exist at the plasma cell stage.
APO-
Taken together, we found ( 1) coregulation of APO-1 and CD54 expression in dense and buoyant tonsillar B cells; ( 2 ) coordinate expression of APO-I and CD54 in some types of normal and neoplastic B cells and simultaneous absence of both molecules in others; (3) abnormal hyperexpression of APO-I in LCL as well as in the majority of mediastinal Bcell lymphomas; and (4) differential expression of APO-1 and CD54 in normal and neoplastic plasma cells.
DISCUSSION
Our results show that APO-I is expressed at relatively low levels in the majority of follicle center B blasts and that For personal use only. on September 24, 2017. by guest www.bloodjournal.org From In areas of sinusoidal B-cell reaction, apoptotic figures are rare (Moller, unpublished). suggesting that apoptosis does not occur in this microenvironment. It can thus be speculated that, under physiologic conditions, surface expression of APO-I in B lymphocytes might not be associated exclusively with imminent cell death: The APO-I molecule might also transduce alternative signals, possibly depending on the presence or the absence of different molecules functionally linked with APO-I.
We show that in the buoyant fraction of tonsillar B-cell isolates, APO-I is coexpressed with ICAM-I (CD54). Furthermore, both molecules are coordinately upregulated by IFN-7 and TNF-a and also by SAC in combination with IL-2. These data confirm findings of Webb et al,34 Tohma et al,35 and Padros et a136 as to CD54 expression in normal B cells. However, the fact that a subset of follicle center B blasts is CD54+ is at variance with Dustin et aL3' Immunohistochemically, we found a coordinate expression of APO-I and CD54 in a subset of follicle center B blasts and a noncoordinate expression of both molecules in thymic medullary B cells (APO-I-, CD54+), in a subset of plasma cells (APO-I-, 
CD54'). and in sinusoidal (.YJW. monocytoid) B cells (APO-I+, CD54-).
Confirming published data,36.3R4 our examination of CD54 expression in LCL and B-cell neoplasias yielded high antigen levels in LCL, an absence of CD54 in Burkitt's lymphoma and in B leukemias, heterogenous CD54 expression in follicle center cell lymphomas, and CD54 positivity in most plasmacytomas. APO-I and CD54 were coordinately expressed in LCL, in mediastinal B-cell lymphoma, in the majority of follicle center cell lymphomas, and, eventually, in hairy cell leukemia. APO-I expression in the absence of CD54 was generally rare but was found in a minority of follicle center cell lymphomas.
ICAM-I (CD54) on B cells binds the ligand LFA-I (CDI la/ CDI 8) on T cells. This interaction was shown to confer stimulatory signals to the B cell during (cognate) intera~tion.~' The natural ligand for APO-I is unknown. lfthis ligand were cell-bound, one might speculate that CD54 might serve a similar costimulatory function modulating the APO-1 mediated signal.
